Biomoda Awarded Patent Expanding Use of CyPath Assay

Biomoda, Inc. (OTCBB: BMOD) received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath® assay to include patient response to cancer therapy during the treatment phase of the disease.

According to John Cousins, President of Biomoda, “Our pilot clinical study demonstrated the CyPath® assay’s utility as a cancer diagnostic. We expect the unique properties of the CyPath® labeling solution that allow it to bind to cancer cells and cause them to fluoresce can also play a significant role in determining the efficacy of cancer treatment.  Doctors will be able to take fluid or tissue samples at intervals during chemotherapy, treat them with the CyPath® solution and compare the results to the baseline assay to see if the percentage of cancerous and abnormal cells is moving in the right direction.”

Read More


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: